broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K17743125-001-08-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.088772 | -2.856406 | 0.114994 | 1 | 1.238353 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000955 |
BRD-K17894950-001-14-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.522556 | 1.16593 | 0.45146 | 0.682551 | 0.015467 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000955 |
BRD-K18961567-001-01-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.000547 | 0.0921 | -0.001705 | 1 | 0.001939 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000955 |
BRD-K19687926-001-04-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.040981 | -4.942867 | -0.096308 | 1 | 0.078295 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000955 |
BRD-K19796430-001-05-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.764521 | -0.231974 | 0.008323 | 0.886903 | 0.053663 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000955 |
BRD-K22064724-001-01-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.052534 | 6.194044 | 0.68659 | 0.844331 | 2.030153 | 2.066864 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000955 |
BRD-K22822991-001-02-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.747029 | 0.09804 | -0.121508 | 0.855425 | 0.003918 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000955 |
BRD-K23228615-001-02-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.338387 | 4.469386 | 0.534217 | 0.822828 | 0.743642 | 0.957434 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000955 |
BRD-K23984367-001-07-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.773563 | 0.086993 | 0.006885 | 0.877365 | 0.011169 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000955 |
BRD-K26026438-001-01-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.624267 | 4.75459 | 0.338012 | 0.929745 | 1.629111 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000955 |
BRD-K26657438-001-15-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.924201 | -0.001372 | -0.00711 | 0.961528 | 285,860,182.622615 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000955 |
BRD-K28822270-001-03-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.333371 | 8.2869 | 0.512141 | 0.959177 | 5.780352 | 6.600046 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000955 |
BRD-K29905972-001-06-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.818201 | -1.513364 | 0.045476 | 0.975067 | 0.0021 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000955 |
BRD-K30577245-001-05-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.68857 | 3.115003 | 0.437763 | 0.903204 | 0.030608 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000955 |
BRD-K31698212-001-02-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.221293 | -4.357153 | 0.103665 | 1 | 0.00219 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000955 |
BRD-K31928526-001-02-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.481705 | -1.063659 | -0.208415 | 0.770515 | 0.044515 | 0.001985 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000955 |
BRD-K33379087-001-07-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.48097 | 0.530063 | 0.071015 | 0.789487 | 0.228948 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000955 |
BRD-K33622447-066-01-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.746102 | 1.362074 | 0.288079 | 0.918177 | 0.442844 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000955 |
BRD-K35520305-001-16-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.766984 | -0.077083 | -0.022988 | 0.896908 | 0.003752 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000955 |
BRD-K36627727-001-05-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.178156 | -0.032487 | -0.02395 | 1 | 10.870706 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000955 |
BRD-K36788280-001-01-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.592182 | -0.159986 | 0.067285 | 0.809336 | 0.033264 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000955 |
BRD-K37379014-001-02-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.50338 | 3.795637 | 0.678317 | 0.841738 | 0.00708 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000955 |
BRD-K38332599-001-01-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.456403 | 0.365921 | 0.256729 | 0.823146 | 0.921268 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000955 |
BRD-K38527262-300-01-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.645347 | -1.843996 | 0.27549 | 0.841033 | 0.023369 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000955 |
BRD-K38852836-001-02-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.545657 | 4.51918 | 0.663217 | 0.802402 | 0.036776 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000955 |
BRD-K39974922-001-04-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.18803 | 0.540788 | 0.081874 | 1 | 0.458744 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000955 |
BRD-K41859756-001-06-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.76114 | 7.933371 | 0.330321 | 0.814002 | 0.00131 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000955 |
BRD-K42495768-001-01-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.607578 | 0.55521 | 0.066772 | 0.835652 | 0.193414 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000955 |
BRD-K42805893-001-04-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.331759 | 0.761948 | 0.546157 | 0.793818 | 0.572203 | 2.389884 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000955 |
BRD-K42828737-001-03-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.482737 | -0.458532 | -0.456698 | 0.712771 | 0.072754 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000955 |
BRD-K42898655-001-01-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.754802 | 0.920631 | 0.169277 | 0.840374 | 0.001076 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000955 |
BRD-K43389675-001-02-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.264569 | 33.695871 | 0.5387 | 0.851192 | 1.403454 | 1.435178 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000955 |
BRD-K44227013-001-06-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.779013 | 3.321885 | 0.341613 | 0.96436 | 10.296255 | 7.760347 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000955 |
BRD-K44408410-001-17-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.132939 | 0.170866 | -0.084533 | 1 | 0.199263 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000955 |
BRD-K44827188-001-06-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.956051 | -1.748278 | -0.022807 | 0.986604 | 0.011711 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000955 |
BRD-K46386702-001-02-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.347416 | 0.708619 | 0.65867 | 0.75826 | 0.302391 | 1.614272 | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000955 |
BRD-K49328571-001-15-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.411588 | 3.278671 | 0.323118 | 1 | 0.078061 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000955 |
BRD-K49350383-001-14-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.552563 | 4.048761 | 0.331258 | 0.924781 | 1.957087 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000955 |
BRD-K50010139-001-01-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.141026 | 0.544583 | -0.03616 | 1 | 60,704,181.982051 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000955 |
BRD-K50168500-001-07-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.005926 | 2.386104 | 0.70404 | 0.880017 | 3.229734 | 3.21383 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000955 |
BRD-K51313569-001-07-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.776437 | -0.020319 | -0.02615 | 0.84063 | 2,202,284,222,246,513,700 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000955 |
BRD-K51791723-003-01-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.107143 | 1.387503 | 0.569641 | 0.761087 | 0.760071 | 0.904355 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000955 |
BRD-K51967704-001-03-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.77856 | 5.841967 | 0.365381 | 0.896578 | 0.10754 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000955 |
BRD-K53414658-001-08-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.253293 | -1.281004 | 0.498688 | 0.894712 | 0.002066 | 0.00119 | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000955 |
BRD-K53972329-001-07-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.907268 | -0.097729 | 0.012856 | 0.951918 | 0.168969 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000955 |
BRD-K54256913-001-08-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.625868 | 0.470862 | 0.233823 | 0.870963 | 0.51599 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000955 |
BRD-K54997624-001-06-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.580676 | 0.861697 | 0.262523 | 0.879247 | 0.680002 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000955 |
BRD-K55187425-236-05-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.502913 | 0.461597 | 0.252636 | 0.698573 | 0.02146 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000955 |
BRD-K56343971-001-14-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.757562 | 4.023338 | 0.175635 | 0.923338 | 0.464813 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000955 |
BRD-K56981171-001-02-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.663899 | -1.503751 | 0.543132 | 0.808758 | 0.152736 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000955 |
BRD-K57080016-001-15-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.694808 | -3.033369 | 0.197096 | 0.951346 | 0.002857 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000955 |
BRD-K57169635-001-04-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.114307 | 1.847461 | 0.458175 | 0.892572 | 3.289658 | 3.785853 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000955 |
BRD-K58435339-001-03-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.942499 | 0.546826 | -0.00518 | 0.967033 | 0.0343 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000955 |
BRD-K58529924-001-01-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.473793 | 0.471731 | 0.720764 | 0.776148 | 0.201922 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000955 |
BRD-K58550667-001-08-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.140822 | 3.027535 | 0.735584 | 0.544556 | 0.003644 | 0.004065 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000955 |
BRD-K59317601-001-05-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.29901 | 0.520982 | 0.389382 | 0.759129 | 0.481284 | 2.767669 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000955 |
BRD-K59369769-001-22-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.21205 | 0.121172 | 0.019626 | 1 | 0.565892 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000955 |
BRD-K60866521-001-07-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.656352 | 0.221557 | -0.086226 | 0.900078 | 6.237976 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000955 |
BRD-K60997853-001-02-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.041521 | 2.382676 | 0.54855 | 0.893079 | 3.847221 | 3.720545 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000955 |
BRD-K61192372-001-08-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.793622 | -0.913068 | 0.058593 | 0.835475 | 1.70247 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000955 |
BRD-K62008436-001-23-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.529486 | 0.028324 | -0.054837 | 0.83134 | 4,234,734.546067 | null | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000955 |
BRD-K62196610-001-01-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.679079 | 0.690141 | 0.0678 | 0.884181 | 0.33803 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000955 |
BRD-K62200014-003-10-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.450747 | -0.110452 | -0.105782 | 0.704078 | 0.329764 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000955 |
BRD-K62391742-001-09-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.716328 | -0.367142 | 0.065656 | 0.849984 | 0.11576 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000955 |
BRD-K62627508-001-01-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.509396 | 0.32497 | -0.017829 | 0.733162 | 0.040803 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000955 |
BRD-K63504947-001-14-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.47193 | 1.58216 | 0.572666 | 0.679575 | 0.027667 | 0.170799 | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000955 |
BRD-K63712959-001-01-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.050134 | 0.105047 | -0.009732 | 1 | 0.057776 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000955 |
BRD-K64881305-001-03-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.099094 | 0.764952 | 0.815349 | 0.615311 | 0.16465 | 0.219766 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000955 |
BRD-K66175015-001-12-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.3827 | 0.61457 | 0.108311 | 0.754625 | 3.531677 | 1.40062 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000955 |
BRD-K69001009-001-02-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.668238 | -3.907848 | 0.029533 | 0.863419 | 0.033147 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000955 |
BRD-K69694239-001-02-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.093088 | 3.202669 | 0.768095 | 0.754202 | 0.720672 | 0.768554 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000955 |
BRD-K69776681-001-03-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | -0.192218 | 0.813375 | 0.559242 | 0.775983 | 2.21108 | 1.482264 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000955 |
BRD-K70301465-001-05-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.826794 | 0.560917 | 0.022749 | 0.871301 | 0.004597 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000955 |
BRD-K70401845-001-15-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.728335 | 0.1694 | -0.03988 | 0.860477 | 0.055663 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000955 |
BRD-K73838513-003-05-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.126031 | 4.011582 | 0.516978 | 0.974493 | 8.296737 | 8.919692 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000955 |
BRD-K74514084-003-09-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.71929 | 2.633697 | 0.23608 | 0.907491 | 0.408391 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000955 |
BRD-K75009076-001-02-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.135039 | 0.438419 | 0.466027 | 0.704219 | 0.57531 | 1.179664 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000955 |
BRD-K76210423-001-01-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.472899 | -0.01533 | -0.024034 | 0.735832 | 0.106037 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000955 |
BRD-K76239644-001-02-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.186349 | 5.03087 | 0.405075 | 0.733127 | 0.414585 | 0.454857 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000955 |
BRD-K76674262-001-03-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.001421 | 0.668494 | 0.686252 | 0.663461 | 0.444753 | 0.446658 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000955 |
BRD-K76908866-001-07-6 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.81925 | 1.844471 | 0.05002 | 0.863303 | 0.00645 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000955 |
BRD-K77625799-001-07-7 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.804613 | 0.003723 | -0.042498 | 0.912377 | 106,212,499,089,569,780,000,000 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000955 |
BRD-K78431006-001-15-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.469177 | 0.076872 | -0.009461 | 0.907205 | 55,609,307.776969 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000955 |
BRD-K79254416-001-21-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.838935 | -0.042573 | -0.007728 | 0.91418 | 1.733834 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000955 |
BRD-K81016934-001-02-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.895352 | 0.225762 | -0.010187 | 0.940593 | 0.020777 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000955 |
BRD-K81418486-001-44-2 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.582036 | 6.30477 | 0.147659 | 0.612291 | 0.001229 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000955 |
BRD-K81473043-001-19-5 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.068176 | -0.009853 | -0.003354 | 1 | 3,339,516,505,977.791 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000955 |
BRD-K82135108-001-04-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.966395 | -1.138554 | 0.002446 | 0.992685 | 0.001589 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000955 |
BRD-K82818427-001-04-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.92513 | 1.263418 | 0.007382 | 0.964771 | 0.104089 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000955 |
BRD-K83029223-001-01-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.641001 | 12.783655 | 0.532879 | 0.81959 | 0.004761 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000955 |
BRD-K83988098-001-02-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 1.002379 | -0.157434 | -0.001813 | 1 | 0.019772 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000955 |
BRD-K85402309-043-01-9 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.709387 | -0.071663 | -0.076973 | 0.837741 | 1.053395 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000955 |
BRD-K85606544-001-09-1 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.943198 | 0.169886 | -0.003583 | 0.959184 | 0.000235 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000955 |
BRD-K86118762-001-01-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.483461 | 0.796121 | 0.133412 | 0.872836 | 1.119382 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000955 |
BRD-K86972824-001-01-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 31.705921 | 0.914783 | -0.081402 | 1 | 277,380,340.085645 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000955 |
BRD-K87737963-001-06-0 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.411 | 0.378105 | 0.177019 | 0.763179 | 0.2937 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000955 |
BRD-K87782578-001-01-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.515158 | 1.698251 | 0.32753 | 0.811548 | 0.23026 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000955 |
BRD-K87909389-003-03-4 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.148049 | 0.238962 | 0.427139 | 0.50675 | 0.017819 | 0.077447 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000955 |
BRD-K88510285-001-17-8 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.090565 | 2.393027 | 0.753294 | 0.598004 | 0.034322 | 0.037311 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000955 |
BRD-K89014967-001-04-3 | ACH-000955 | SNU407_LARGE_INTESTINE | MTS010 | 1 | 0.239602 | 1.772575 | 0.042014 | 0.980264 | 13.830423 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000955 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.